We are live on ! Find out more
SNOA icon

Sonoma Pharmaceuticals
SNOA

15 hedge funds and large institutions have $2.12M invested in Sonoma Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0.05% → 0.05% (-0%)

6% less funds holding

Funds holding: 16 → 15 (-1)

24% less capital invested

Capital invested by funds: $2.78M → $2.12M (-$667K)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

50% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 6

Holders
15
Holders Change
-1
Holders Change %
-6.25%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
6
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MCC
Malaga Cove Capital
California
+$52K
2
Morgan Stanley
Morgan Stanley
New York
+$3.25K
3
BlackRock
BlackRock
New York
+$2.17K
4
LTFS
Ladenburg Thalmann Financial Services
Florida
+$1.08K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$102K
2
Renaissance Technologies
Renaissance Technologies
New York
-$14.1K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$13K
4
Deutsche Bank
Deutsche Bank
Germany
-$9K
5
UBS Group
UBS Group
Switzerland
-$3.25K
Name Holding Trade Value Shares
Change 		Change in
Stake
BA
1
Bard Associates
Illinois
$639K -$2.17K -2 -0.3%
JAM
2
JW Asset Management
Florida
$527K – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$451K -$102K -94 -16%
Renaissance Technologies
4
Renaissance Technologies
New York
$193K -$14.1K -13 -6%
BlackRock
5
BlackRock
New York
$149K +$2.17K +2 +1%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$68K – – –
MCC
7
Malaga Cove Capital
California
$45K +$52K +48 New
Morgan Stanley
8
Morgan Stanley
New York
$17K +$3.25K +3 +20%
Acadian Asset Management
9
Acadian Asset Management
Massachusetts
$5K -$13K -12 -71%
UBS Group
10
UBS Group
Switzerland
$5K -$3.25K -3 -33%
Bank of America
11
Bank of America
North Carolina
$5K – – –
Wells Fargo
12
Wells Fargo
California
$5K – – –
Bank of Montreal
13
Bank of Montreal
Ontario, Canada
$3K – – –
HFM
14
Hartford Financial Management
Connecticut
$2K -$2.17K -2 -40%
LTFS
15
Ladenburg Thalmann Financial Services
Florida
$2K +$1.08K +1 +100%
RE
16
RBC Europe
United Kingdom
$131 – – –
Deutsche Bank
17
Deutsche Bank
Germany
– -$9K -8 Closed
JP Morgan Chase
18
JP Morgan Chase
New York
– -$2K -2 Closed

SNOA Hedge Fund Activity: Q3 2017 in Review

15 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q3 2017, worth a combined $2.12M — down 24% from $2.78M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of SNOA and 1 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 3 added.

The largest buyer was Malaga Cove Capital, opening a new position worth an estimated $52K. The largest seller was Vanguard Group, cutting an estimated $102K.

  • 15 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q3 2017, down from 16 in Q2 2017.
  • Funds reported $2.12M of Sonoma Pharmaceuticals stock for Q3 2017, down 24% quarter-over-quarter.
  • 1 fund opened new Sonoma Pharmaceuticals positions in Q3 2017 and 2 closed out, a net change of -1 holder.
  • The largest Sonoma Pharmaceuticals buyer in Q3 2017 was Malaga Cove Capital, an estimated $52K added.
  • The largest Sonoma Pharmaceuticals seller in Q3 2017 was Vanguard Group, an estimated $102K sold.

Based on aggregated 13F filings for Q3 2017.